Cite
HARVARD Citation
Zent, C. et al. (n.d.). A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG‐ACRIN cancer research group (E1908). American journal of hematology. 91 (3), pp. 308-312. [Online].